3.28  0.01 (0.31%)		07-26 16:00
Open: 3.35 High: 3.45 Volume: 1,360,708		Pre. Close: 3.27 Low: 3.2 Market Cap: 852(M)

Short term
Mid term
Targets	6-month :	4.02	1-year :	4.7
Resists	First :	3.45	Second :	4.02
Pivot price	2.99
Supports	First :	2.56	Second :	2
MAs	MA(5) :	3.18	MA(20) :	2.81
	MA(100) :	2.28	MA(250) :	2.22
MACD	MACD :	0.2	Signal :	0.2
%K %D	K(14,3) :	88	D(3) :	86.4
RSI	RSI(14): 69.7
52-week	High :	3.45	Low :	1.5

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ERAS ] has closed below upper band by 21.6%. Bollinger Bands are 46% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	3.45 - 3.47	3.47 - 3.48
Low:	3.17 - 3.18	3.18 - 3.19
Close:	3.25 - 3.28	3.28 - 3.3

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

Sat, 20 Jul 2024
Erasca (NASDAQ:ERAS) Reaches New 52-Week High at $3.33 - Defense World

Wed, 17 Jul 2024
Erasca (NASDAQ:ERAS) Shares Gap Up to $2.97 - Defense World

Sun, 14 Jul 2024
CVI Holdings LLC Invests $3 Million in Erasca, Inc. (NASDAQ:ERAS) - MarketBeat

Tue, 04 Jun 2024
Should You Buy Erasca, Inc. (ERAS) After Golden Cross? - Yahoo Finance

Thu, 23 May 2024
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying - Benzinga

Tue, 21 May 2024
Erasca buys-in assets from two China biotechs, slashes workforce - BioWorld Online

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	273 (M)
Shares Float	114 (M)
Held by Insiders	14.7 (%)
Held by Institutions	55.7 (%)
Shares Short	20,010 (K)
Shares Short P.Month	14,080 (K)

EPS	-0.84
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.9
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-21.4 %
Return on Equity (ttm)	-37.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.52
Qtrly Earnings Growth	0 %
Operating Cash Flow	-108 (M)
Levered Free Cash Flow	-57 (M)

PE Ratio	-3.91
PEG Ratio	0.2
Price to Book value	1.71
Price to Sales	0
Price to Cash Flow	-8.28

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.